Literature DB >> 3279056

Joint oxygen-glucose deprivation as the cause of necrosis in a tumor analog.

L Hlatky1, R K Sachs, E L Alpen.   

Abstract

The sandwich system was recently developed as an in vitro tumor analog. Like spheroids, sandwiches are organized, multicellular systems in which the interplay between diffusion and consumption leads to the formation of spatial gradients; a necrotic center and a viable cell border subsequently develop. Using sandwiches of the 9L and V79 cell lines, the effects of oxygen and glucose deprivation on the onset and formation of necrosis were investigated. The data indicate that in sandwiches necrosis is a result of a shortage of both substances. Complementary cell monolayer experiments to determine a number of consumption parameters were performed. On the basis of the data, we propose a joint oxygen-glucose deprivation model for V79 cell necrosis. It is assumed a cell dies when oxygen deprivation in conjunction with glucose deprivation lowers the cell's ATP production rate below a critical value. Interactions of the concentrations and consumptions of oxygen and glucose are analyzed theoretically; concentration profiles are obtained by numerically solving coupled non-linear integral equations arising from the diffusion equation. The predicted viable border widths are in good agreement with the observed values.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3279056     DOI: 10.1002/jcp.1041340202

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

1.  Photodynamic enhancement of doxorubicin cytotoxicity.

Authors:  K W Lanks; J P Gao; T Sharma
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

2.  Emergent Stratification in Solid Tumors Selects for Reduced Cohesion of Tumor Cells: A Multi-Cell, Virtual-Tissue Model of Tumor Evolution Using CompuCell3D.

Authors:  Maciej H Swat; Gilberto L Thomas; Abbas Shirinifard; Sherry G Clendenon; James A Glazier
Journal:  PLoS One       Date:  2015-06-17       Impact factor: 3.240

3.  The role of reduced nicotinamide adenine dinucleotide phosphate in glucose- and temperature-dependent doxorubicin cytotoxicity.

Authors:  J P Gao; S Friedman; K W Lanks
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Modelling the interplay between hypoxia and proliferation in radiotherapy tumour response.

Authors:  J Jeong; K I Shoghi; J O Deasy
Journal:  Phys Med Biol       Date:  2013-06-21       Impact factor: 3.609

5.  Delivery-corrected imaging of fluorescently-labeled glucose reveals distinct metabolic phenotypes in murine breast cancer.

Authors:  Amy E Frees; Narasimhan Rajaram; Samuel S McCachren; Andrew N Fontanella; Mark W Dewhirst; Nimmi Ramanujam
Journal:  PLoS One       Date:  2014-12-19       Impact factor: 3.240

Review 6.  Experimental models for assaying microvascular endothelial cell pathophysiology in stroke.

Authors:  Susanna Camós; Judith Mallolas
Journal:  Molecules       Date:  2010-12-10       Impact factor: 4.411

7.  Reducing the hypoxic fraction of a tumour model by growth in low glucose.

Authors:  L Hlatky; R K Sachs; C S Ring
Journal:  Br J Cancer       Date:  1989-03       Impact factor: 7.640

8.  Changes in tumour morphology with alterations in oxygen availability: further evidence for oxygen as a limiting substrate.

Authors:  D G Hirst; V K Hirst; B Joiner; V Prise; K M Shaffi
Journal:  Br J Cancer       Date:  1991-07       Impact factor: 7.640

9.  Variable presence of hypoxia in M006 human glioma spheroids and in spheroids and xenografts of clonally derived sublines.

Authors:  A J Franko; M B Parliament; M J Allalunis-Turner; B G Wolokoff
Journal:  Br J Cancer       Date:  1998-11       Impact factor: 7.640

Review 10.  Regulation of Tumor Progression by Programmed Necrosis.

Authors:  Su Yeon Lee; Min Kyung Ju; Hyun Min Jeon; Eui Kyong Jeong; Yig Ji Lee; Cho Hee Kim; Hye Gyeong Park; Song Iy Han; Ho Sung Kang
Journal:  Oxid Med Cell Longev       Date:  2018-01-31       Impact factor: 6.543

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.